Strides Pharma (SA) Proprietary Limited Registration number: 2013/ 235090/ 07 Balance Sheet as at March 31, 2025

				Amount in ZAR
		Note No.	31-Mar-25	31-Mar-24
Α	ASSETS			
1	Non-current assets			
	(a) Other intangible assets		10,847,005	12,483,384
	(b) Intangibles assets under development		944,290	-
	Total non-current assets		11,791,296	12,483,384
II	Current assets			
	(a) Inventories		92,156,442	41,578,881
	(b) Financial assets			
	(i) Trade receivables	1	46,508,832	25,942,553
	(ii) Cash and cash equivalents	2	4,072	428,460
	(c) Other Current Assets	3	1,195,921	1,776,485
	Total current assets		139,865,268	69,726,379
	TOTAL ASSETS	<u> </u>	151,656,563	82,209,763
В	EQUITY AND LIABILITIES			
ı	Equity			
	(a) Equity share capital	4	100	100
	(b) Reserves and Surplus	5	(16,603,619)	(30,632,644)
	Total Equity		(16,603,519)	(30,632,544)
П	Liabilities			
1	Non-current liabilities			
	(a) Financial liabilities			
	(i) Borrowings	6	81,102,924	76,490,292
	Total non-current liabilities		81,102,924	76,490,292
2	Current liabilities			
	(a) Financial liabilities			
	(i) Trade payables	7	84,378,841	36,113,459
	(b) Other current liabilities	8	2,653,258	24,405
	(c) Provisions	9	125,060	214,150
	Total current liabilities		87,157,159	36,352,015
	TOTAL EQUITY AND LIABILITIES		151,656,563	82,209,763

Strides Pharma (SA) Proprietary Limited Registration number: 2013/ 235090/ 07 Statement of Profit and Loss for the year ended March 31, 2025

			Amount in ZAR
Particulars	Note No.	31-Mar-25	31-Mar-24
1 Revenue from operations	10	170,738,600	104,751,492
2 Other Income	11	1,118,291	-
3 Total Revenue (1+2)	_	171,856,891	104,751,492
4 Expenses			
(a) Cost of material consumed	12	140,523,964	98,647,226
(b) Employee benefits expense	13	891,577	1,109,344
(c) Finance costs	14	8,748,426	4,868,783
(d) Depreciation and amortisation expense		899,590	910,580
(e) Other expenses	15	6,764,310	7,656,364
Total expenses	_	157,827,867	113,192,297
5 Profit / (Loss) before taxes (3-4)	_	14,029,024	(8,440,805)
6 Tax Expense:			
(a) Current tax		-	-
(b) Deferred tax		-	8,519,834
Total tax expenses	_	-	8,519,834
7 Profit / (Loss) for the year after tax		14,029,024	(16,960,639)

Strides Pharma (SA) Proprietary Limited Notes forming part of financial statement

Note No.

1 Trade receivables

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Unsecured		
Considered good	46,508,832	25,942,553
Considered doubtful		
	46,508,832	25,942,553
Less: Allowance for doubtful trade receivables		
Total	46,508,832	25,942,553

2 Cash and cash equivalents

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Balances with banks:		
In current accounts	4,072	428,460
Total	4,072	428,460

3 Other current assets

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Unsecured, considered good		
Advances to other related entities	-	156,046
Advances to vendors	8,303	
- VAT receivable	-	1,470,561
- Advance tax	772,116	-
Prepaid expenses	415,502	305,924
Total	1,195,921	1,776,485

4 Share capital

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Issued, subscribed and fully paid-up		
Equity share capital	100	100
Total	100	100

5 Reserves and surplus

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Securities premium account		
Opening balance	9,267,641	9,267,641
Add : Premium on shares issued during the year	-	-
Closing balance	9,267,641	9,267,641
Surplus in statement of profit and loss		
Opening balance	(39,900,284)	(22,939,646)
Add: Profit / (Loss) for the year	14,029,024	(16,960,639)
Closing balance	(25,871,260)	(39,900,285)
Tabel	(45,502,540)	(20, 622, 644)
Total	(16,603,619)	(30,632,644)

Strides Pharma (SA) Proprietary Limited Notes forming part of financial statement Note No.

6 Long term borrowings

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Unsecured loan from others	11,271,636	10,394,924
Loan from related Parties	69,831,288	66,095,368
Total	81,102,924	76,490,292

7 Trade payables

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Trade payable	84,378,841	36,113,459
Total	84,378,841	36,113,459

8 Other current liabilities

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Advance received from customer	2,607	1,553
Statutory dues	2,650,651	22,852
Total	2,653,258	24,405

9 Provisions

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Provision for expenses	125,060	71,023
Provision for Leave encashment	-	143,128
Total	125,060	214,150

10 Revenue from operations

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Sale of Product	170,738,600	104,751,492
Total	170,738,600	104,751,492

11 Other Income

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Exchange fluctuation gain - Not realized	1,118,291	-
Total	1,118,291	-

12 Cost of materials consumed

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Opening stock	41,578,881	9,943,650
Add: Purchases	191,101,525	130,282,457
Closing stock	92,156,442	41,578,881
Total	140,523,964	98,647,226

Strides Pharma (SA) Proprietary Limited Notes forming part of financial statement

Note No.

13 Employee benefit expenses

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Salaries and wages	881,472	1,099,944
Staff Welfare	10,104	9,400
Total	891,577	1,109,344

14 Finance cost

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Bank charges	7,967	9,332
Intra group - finace cost	7,863,747	4,108,106
Interest on term loans	876,713	751,345
Total	8,748,426	4,868,783

15 Other expenses

Amount in ZAR

Particulars	31-Mar-25	31-Mar-24
Testing and analytical Expenses	390,631	1,746,232
Freight and forwarding	4,532,274	2,766,485
Insurance	158,755	-
Rates & taxes	380,400	-
Conveyance & travelling	473	-
Advertisement & Selling expenses	41,665	-
Net loss on foreign currency transactions	-	896,868
Professional fees & Legal fees	251,681	720,765
Other Expenses	1,008,431	1,526,015
Total	6,764,310	7,656,364